Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 25.65 USD 2.07% Market Closed
Market Cap: 145.4B USD
Have any thoughts about
Pfizer Inc?
Write Note

Wall Street
Price Targets

PFE Price Targets Summary
Pfizer Inc

Wall Street analysts forecast PFE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PFE is 32.95 USD with a low forecast of 25.25 USD and a high forecast of 47.25 USD.

Lowest
Price Target
25.25 USD
2% Downside
Average
Price Target
32.95 USD
28% Upside
Highest
Price Target
47.25 USD
84% Upside

PFE Last Price Targets
Pfizer Inc

The latest public price target was made on Oct 30, 2024 by Chris Shibutani from Goldman Sachs , who expects PFE stock to rise by 29% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Chris Shibutani
Goldman Sachs
33 USD
Upside 29%
3 weeks ago
Oct 30, 2024
Pfizer (PFE) PT Raised to $33 at Goldman Sachs
StreetInsider
Courtney Breen
Bernstein
32 USD
Upside 25%
1 month ago
Oct 17, 2024
Pfizer initiated with a Market Perform at Bernstein
TheFly
Carter Gould
Barclays
32 USD
Upside 25%
1 month ago
Sep 25, 2024
Pfizer withdrawal raises business development questions, says Barclays
TheFly
Narumi Nakagiri
Daiwa
34 USD
Upside 33%
3 months ago
Aug 7, 2024
Daiwa Securities Upgrades Pfizer (PFE) to Outperform (2)
StreetInsider
Mohit Bansal
Wells Fargo
30 USD
Upside 17%
3 months ago
Jul 31, 2024
Pfizer price target raised to $30 from $28 at Wells Fargo
TheFly
Chris Shibutani
Goldman Sachs
34 USD
Upside 33%
3 months ago
Jul 31, 2024
Pfizer (PFE) PT Raised to $34 at Goldman Sachs
StreetInsider
Vamil Divan
Guggenheim
36 USD
Upside 40%
3 months ago
Jul 30, 2024
Pfizer Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Benzinga
Carter Gould
Barclays
30 USD
Upside 17%
4 months ago
Jul 10, 2024
Pfizer price target raised to $30 from $28 at Barclays
TheFly
Evan Seigerman
BMO Capital
36 USD
Upside 40%
6 months ago
May 22, 2024
Pfizer cost reduction program a positive for the shares, says BMO
TheFly
Louise Chen
Cantor Fitzgerald
45 USD
Upside 75%
9 months ago
Feb 14, 2024
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga
Thomas Yeh
Morgan Stanley
20 USD
Downside 22%
11 months ago
Dec 14, 2023
Harmonic To Rally Over 80%? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga
Terence Flynn
Morgan Stanley
37 USD
Upside 44%
11 months ago
Nov 27, 2023
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Benzinga
Unknown Analyst
Morgan Stanley
45 USD
Upside 75%
1 year ago
Feb 1, 2023
Morgan Stanley Maintains Equal-Weight on Pfizer, Lowers Price Target to $45
Benzinga
Unknown Analyst
Atlantic Equities
46 USD
Upside 79%
1 year ago
Feb 1, 2023
Atlantic Equities Maintains Neutral on Pfizer, Lowers Price Target to $46
Benzinga
Unknown Analyst
Leerink Partners
48 USD
Upside 87%
1 year ago
Feb 1, 2023
SVB Leerink Maintains Market Perform on Pfizer, Lowers Price Target to $48
Benzinga
Unknown Analyst
Credit Suisse
50 USD
Upside 95%
1 year ago
Feb 1, 2023
Credit Suisse Maintains Outperform on Pfizer, Lowers Price Target to $50
Benzinga
Unknown Analyst
Barclays
44 USD
Upside 72%
1 year ago
Feb 1, 2023
Barclays Maintains Equal-Weight on Pfizer, Lowers Price Target to $44
Benzinga
Show More Price Targets
Show Less Price Targets
Chris Shibutani
Goldman Sachs
Price Target 33 USD
Upside/Downside 29%
View Source
Courtney Breen
Bernstein
Price Target 32 USD
Upside/Downside 25%
View Source
Carter Gould
Barclays
Price Target 32 USD
Upside/Downside 25%
View Source
Narumi Nakagiri
Daiwa
Price Target 34 USD
Upside/Downside 33%
View Source
Mohit Bansal
Wells Fargo
Price Target 30 USD
Upside/Downside 17%
View Source
Chris Shibutani
Goldman Sachs
Price Target 34 USD
Upside/Downside 33%
View Source
Vamil Divan
Guggenheim
Price Target 36 USD
Upside/Downside 40%
View Source
Carter Gould
Barclays
Price Target 30 USD
Upside/Downside 17%
View Source
Evan Seigerman
BMO Capital
Price Target 36 USD
Upside/Downside 40%
View Source
Louise Chen
Cantor Fitzgerald
Price Target 45 USD
Upside/Downside 75%
View Source
Thomas Yeh
Morgan Stanley
Price Target 20 USD
Upside/Downside 22%
View Source
Terence Flynn
Morgan Stanley
Price Target 37 USD
Upside/Downside 44%
View Source
Unknown Analyst
Morgan Stanley
Price Target 45 USD
Upside/Downside 75%
View Source
Unknown Analyst
Atlantic Equities
Price Target 46 USD
Upside/Downside 79%
View Source
Unknown Analyst
Leerink Partners
Price Target 48 USD
Upside/Downside 87%
View Source
Unknown Analyst
Credit Suisse
Price Target 50 USD
Upside/Downside 95%
View Source
Unknown Analyst
Barclays
Price Target 44 USD
Upside/Downside 72%
View Source
Show More Price Targets
Show Less Price Targets
Pfizer Inc Competitors:
Price Targets
4503
Astellas Pharma Inc
27% Upside
002294
Shenzhen Salubris Pharmaceuticals Co Ltd
3% Upside
4521
Kaken Pharmaceutical Co Ltd
18% Downside
TLRY
Tilray Brands Inc
71% Upside
DPHARMA
Duopharma Biotech Bhd
20% Upside
VY4
SNDL Inc
76% Upside
HITI
High Tide Inc
69% Upside
ERIS
Eris Lifesciences Ltd
12% Upside

Revenue
Forecast

Revenue Estimate
Pfizer Inc

For the last 8 years the compound annual growth rate for Pfizer Inc's revenue is 2%. The projected CAGR for the next 3 years is 3%.

2%
Past Growth
3%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Pfizer Inc

For the last 8 years the compound annual growth rate for Pfizer Inc's operating income is -1%. The projected CAGR for the next 3 years is 18%.

-1%
Past Growth
18%
Estimated Growth
Estimates Accuracy
-22%
Average Miss

Net Income
Forecast

Net Income Estimate
Pfizer Inc

For the last 8 years the compound annual growth rate for Pfizer Inc's net income is -14%. The projected CAGR for the next 3 years is 103%.

-14%
Past Growth
103%
Estimated Growth
Estimates Accuracy
-35%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PFE's stock price target?
Price Target
32.95 USD

According to Wall Street analysts, the average 1-year price target for PFE is 32.95 USD with a low forecast of 25.25 USD and a high forecast of 47.25 USD.

What is Pfizer Inc's Revenue forecast?
Projected CAGR
3%

For the last 8 years the compound annual growth rate for Pfizer Inc's revenue is 2%. The projected CAGR for the next 3 years is 3%.

What is Pfizer Inc's Operating Income forecast?
Projected CAGR
18%

For the last 8 years the compound annual growth rate for Pfizer Inc's operating income is -1%. The projected CAGR for the next 3 years is 18%.

What is Pfizer Inc's Net Income forecast?
Projected CAGR
103%

For the last 8 years the compound annual growth rate for Pfizer Inc's net income is -14%. The projected CAGR for the next 3 years is 103%.

Back to Top